Certara, Inc. (NASDAQ:CERT - Get Free Report)'s stock price shot up 6.7% during trading on Thursday . The stock traded as high as $12.59 and last traded at $12.78. 599,203 shares changed hands during trading, a decline of 65% from the average session volume of 1,717,609 shares. The stock had previously closed at $11.97.
Analysts Set New Price Targets
CERT has been the subject of a number of recent research reports. Craig Hallum initiated coverage on shares of Certara in a research note on Monday, September 29th. They issued a "buy" rating and a $16.00 price objective for the company. Weiss Ratings reiterated a "sell (d)" rating on shares of Certara in a research report on Wednesday, October 8th. Barclays increased their target price on shares of Certara from $14.00 to $16.00 and gave the stock an "overweight" rating in a research report on Thursday, October 2nd. KeyCorp increased their target price on shares of Certara from $15.00 to $16.00 and gave the stock an "overweight" rating in a research report on Wednesday, October 8th. Finally, Morgan Stanley began coverage on shares of Certara in a report on Thursday, July 3rd. They set an "equal weight" rating and a $16.00 price objective on the stock. Six equities research analysts have rated the stock with a Buy rating, five have given a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, the company presently has a consensus rating of "Hold" and an average target price of $15.63.
Get Our Latest Stock Analysis on CERT
Certara Stock Up 5.1%
The company has a market cap of $2.02 billion, a P/E ratio of 251.55 and a beta of 1.45. The company has a current ratio of 2.16, a quick ratio of 2.16 and a debt-to-equity ratio of 0.27. The firm's 50 day moving average price is $11.47 and its 200-day moving average price is $11.46.
Certara (NASDAQ:CERT - Get Free Report) last issued its earnings results on Wednesday, August 6th. The company reported $0.07 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.10 by ($0.03). The business had revenue of $104.57 million during the quarter, compared to the consensus estimate of $104.14 million. Certara had a net margin of 1.97% and a return on equity of 5.11%. The firm's revenue for the quarter was up 12.1% compared to the same quarter last year. During the same period last year, the business posted $0.07 EPS. As a group, equities research analysts expect that Certara, Inc. will post 0.28 EPS for the current year.
Insiders Place Their Bets
In related news, insider Leif E. Pedersen sold 51,224 shares of Certara stock in a transaction that occurred on Tuesday, September 9th. The shares were sold at an average price of $10.92, for a total transaction of $559,366.08. Following the transaction, the insider owned 73,979 shares of the company's stock, valued at $807,850.68. This trade represents a 40.91% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 2.33% of the stock is owned by insiders.
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently bought and sold shares of the company. AdvisorNet Financial Inc bought a new position in Certara during the 2nd quarter worth approximately $25,000. Caitong International Asset Management Co. Ltd acquired a new stake in Certara during the 1st quarter worth approximately $31,000. AlphaQuest LLC acquired a new stake in Certara during the 1st quarter worth approximately $39,000. Osaic Holdings Inc. raised its holdings in Certara by 50.7% during the 2nd quarter. Osaic Holdings Inc. now owns 3,491 shares of the company's stock worth $41,000 after buying an additional 1,175 shares during the period. Finally, Elevation Point Wealth Partners LLC acquired a new stake in Certara during the 2nd quarter worth approximately $59,000. Institutional investors own 73.96% of the company's stock.
About Certara
(
Get Free Report)
Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Certara, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Certara wasn't on the list.
While Certara currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.